priors.science/reviews/btk-inhibitors-in-multiple-sclerosis

Btk Inhibitors in Multiple Sclerosis

The current evidence on 15 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

15claims tracked

71primary papers reviewed

4 May 2026latest evidence review

Weeklyre-scored against new papers

3 Established · 7 Likely · 4 Uncertain · 0 Doubtful · 1 Refuted | four-reviewer panel · PICO Framework

SignalClaimStandingEvidence certaintyCorpus

StableSerum neurofilament light chain is a validated biomarker of neuroaxonal injury in multiple sclerosis that predicts long-term disability outcomes and monitors treatment response.BioEstablished93%—

StableBTK is expressed in microglia and macrophages within active and chronic active multiple sclerosis lesions, with significantly elevated levels compared with normal-appearing white matter.MechEstablished92%—

StableCNS-penetrant BTK inhibitors achieve bioactive concentrations in cerebrospinal fluid at therapeutic doses used in multiple sclerosis clinical trials.MechEstablished91%—

StableBTK inhibitors developed for multiple sclerosis are not associated with the cardiovascular adverse events — including atrial fibrillation and major bleeding — characteristic of ibrutinib in haematological malignancies.SafeLikely79%—

StableBTK inhibitors reduce gadolinium-enhancing T1 lesions in relapsing multiple sclerosis compared with placebo.RelapsLikely75%—

StableBTK inhibitors used in multiple sclerosis clinical trials are associated with liver enzyme elevations that can progress to clinically significant hepatotoxicity in a minority of patients.SafeLikely74%—

StableBrain-penetrant BTK inhibitors reduce 6-month confirmed disability progression in non-relapsing secondary progressive multiple sclerosis.ProgLikely72%—

StableBTK inhibitors used in multiple sclerosis preserve circulating B cell counts and immunoglobulin levels during treatment, unlike anti-CD20 therapies.SafeLikely71%—

StableCNS-penetrant BTK inhibition reduces neurodegeneration and axonal injury markers in preclinical models of secondary progressive multiple sclerosis.ProgLikely68%—

StableBTK inhibition modulates microglial activation in neuroinflammation models independently of peripheral B cell depletion, providing a mechanistic basis distinct from anti-CD20 therapies.MechLikely67%—

StableBTK inhibitor treatment reduces serum neurofilament light chain levels in patients with multiple sclerosis, consistent with reduced neuroaxonal injury.BioUncertain63%—

StableCNS-penetrant BTK inhibition preferentially targets the smouldering MS phenotype characterised by chronic active lesions with microglial rims.MechUncertain61%—

StableBTK inhibitors reduce the volume of slowly expanding lesions — an MRI marker of chronic active plaques — in relapsing multiple sclerosis.RelapsUncertain51%—

StableBTK inhibitors reduce 6-month confirmed disability worsening in relapsing multiple sclerosis independently of relapse suppression.ProgUncertain43%—

StableBTK inhibitors are superior to teriflunomide for annualized relapse rate in relapsing multiple sclerosis.RelapsRefuted8%—

Standing — what the evidence certainty means

Established≥ 85%Strong, consistent evidence. Unlikely to change.

Likely65–84%Well supported, with some gaps or indirect evidence.

Uncertain40–64%Mixed or limited evidence. Genuinely open.

Doubtful15–39%Little support; the weight of evidence leans against it.

Refuted< 15%The evidence contradicts it — confidently false as stated.

Recent signal

strengthenedNew evidence raised the certainty since the last review.

weakenedNew evidence lowered the certainty since the last review.

newA claim added to the review recently.

StableNo recent change to the standing.

Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.

Update your priors.Track this topic